Targeting cytokines in inflammatory bowel disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36516267.
- Also identified by DOI 10.1126/scitranslmed.abq4473.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting cytokines in inflammatory bowel disease (IBD) is a useful clinical approach. Potential therapies for IBD include regulatory T cell transfer to restore cytokine balance, blocking proinflammatory cytokines (e.g., IL-12 and IL-23) or their receptors (sIL-6R and IL-36R), or inhibiting signaling kinases (e.g., JAK). An emerging trend in IBD therapy is to combine several anti-cytokine agents simultaneously.
Medical subject headings
- Cytokines
- Inflammatory Bowel Diseases